Вплив ад’ювантної терапії на ефективність лікування хворих із хронічною серцевою недостатністю та проміжною фракцією викиду лівого шлуночка
Gennadii Kochuiev, Марина Миколаївна Кочуєва, Іван Олександрович Грек et al. · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · 2026
The objective: to evaluate the effect of adjunctive therapy including dietary supplement Solargin Q10 on cardiovascular function, endothelial function (EF), microcirculation, oxidative status, and clinical outcomes in patients with chronic heart failure (CHF) and mildly reduced left ventricular ejection fraction (LVEF). Materials and methods. The study included 60 patients aged 61–70 years with post-infarction cardiosclerosis, stage III arterial hypertension, and CHF stage IIA (NYHA class III), with LVEF of 41–49%. Patients were divided into 2 groups: the 1st group (n = 30) received standard quadruple therapy for CHF, while the 2nd group (n = 30) additionally received Solargin Q10, 1 sachet daily. The follow-up period was 8 weeks. Echocardiographic parameters, endothelium-dependent vasodilation (EDV), microcirculatory parameters, exercise tolerance, lipid profile, and markers of oxidative stress were assessed. Results. The addition of Solargin Q10 resulted in a significant improvement in EF: EDV increased to 6.12% vs 4.25% in the group of standard therapy, while the peak blood flow – to 372.8 mL/min vs 301.8 mL/min, respectively (p < 0.05). Improved microvascular reactivity, a reduction in microcirculatory disturbances, and a tendency toward decreased platelet aggregation were observed. Adjunctive therapy was associated with reduced levels of malondialdehyde and diene conjugates, an increased activity of superoxide dismutase, catalase, and total antioxidant activity (p < 0.05). The lipid profile demonstrated reductions in total cholesterol, low-density lipoprotein cholesterol, and triglycerides, along with an increase in high-density lipoprotein cholesterol levels (p < 0.05). Parameters of LV diastolic function were the most responsive to therapy. Exercise tolerance increased by 18.4% compared with 6.5% in the standard therapy group (p < 0.05). Conclusions. The addition of Solargin Q10 to standard CHF therapy in patients with mildly reduced LVEF contributes to improvements in EF and microcirculation, oxidative and lipid status, as well as overall cardiac function. The greatest benefit was observed in patients with a pseudonormal pattern of diastolic dysfunction.
Cited by 0 works.